Summary of selected cases.

Subjects were divided in three groups according to neuropathological and clinical criteria: clinic-pathological Alzheimer’s disease (CP-AD), pathological/preclinical Alzheimer’s disease (P-AD), and normal older individuals (N). Sample ID, sample identification; Age, age at death in years; F, female; M, male; Braak, Braak stage; CERAD, Consortium to Establish a Registry for Alzheimeŕs Disease score; CDR, Clinical Dementia Ratio score; PMI, post-mortem interval in hours.本研究依据神经病理与临床标准将受试者分为三组：临床病理型阿尔茨海默病（clinic-pathological Alzheimer’s Disease, CP-AD）、病理/临床前阿尔茨海默病（pathological/preclinical Alzheimer’s Disease, P-AD）以及正常老年受试者（N）。各字段说明如下：样本编号（Sample ID）：样本标识；年龄（Age）：死亡时年龄，单位为年；性别：F代表女性（female），M代表男性（male）；Braak分期（Braak stage）；CERAD评分：阿尔茨海默病登记联盟（Consortium to Establish a Registry for Alzheimer’s Disease, CERAD）评分；CDR评分：临床痴呆比率（Clinical Dementia Ratio, CDR）评分；PMI：死后间隔时间（post-mortem interval, PMI），单位为小时。